SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot
Status:
Recruiting
Trial end date:
2025-05-30
Target enrollment:
Participant gender:
Summary
SGLT2i have been shown to reduce risk for mortality, progression of chronic kidney disease,
and cardiovascular outcomes in these populations. Yet, because SGLT2i can have an acute
hemodynamic effect on kidney function, in clinical practice providers are wary of providing
these medications to patients who have established indications but recently had acute kidney
injury (AKI).
This is a pilot interventional study to collect process-data (measures of recruitment and
measures of adherence) that can be used to establish feasibility for a larger pilot
randomized trial in the future. The study aims to conduct a small randomized intervention
trial with two arms, with approximately 10-12 patients in the intervention arm and 5-6 in the
control arm. The intervention will be providing a prescription for a SGLT2i based on
established criteria for this FDA-approved class of drugs, and the control will be usual care
(through which, control arm participants will also have access to this FDA-approved class of
drugs - expect receipt of a SGLT2i in the control arm to be rare, but a degree of crossover
will be expected).